November 05, 2019

Azurity Pharmaceuticals, Inc. v. Alkem Laboratories Ltd.

View recent docket activity

Reflects complaints, answers, motions, orders and trial notes entered from Jan. 1, 2011.
Additional or older documents may be available in Pacer.

Coverage

  1. February 13, 2023

    Azurity Loses Hypertension Drug Patent Trial Against Alkem

    A federal judge sitting in Delaware ruled Friday that several claims of two patents on Azurity Pharmaceuticals Inc.'s hypertension drug Epaned are invalid, handing a win to Alkem Laboratories Ltd., which is planning a generic version of the drug.

1 other articles on this case. View all »

Parties

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Direct access to case information and documents.
  • All significant new filings across U.S. federal district courts, updated hourly on business days.
  • Full-text searches on all patent complaints in federal courts.
  • No-fee downloads of the complaints and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

View the parties now

Already a subscriber? Click here to login